Price Chart

Price Chart

Profile

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.
URL http://www.patrys.com
Investor Relations URL N/A
HQ State/Province Western Australia (WA)
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.
URL http://www.patrys.com
Investor Relations URL N/A
HQ State/Province Western Australia (WA)
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A